Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T16:26:54.394Z.
Calculation as of: 2026-10-06T16:26:54.394Z.
Quote observation: 2026-10-06T16:25:14.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8e2f3ec51e074b036058196f7f903a3cac1545bb57f25a27b7ce4fd0c255fbf9
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Galectin Therapeutics Inc.
Market Cap
$241.69M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$243.62M
EV/Sales Ratio
N/A
TTM Avg
2.84x
3Y Avg
2.61x
5Y Avg
2.12x
Market Cap
$242.34M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$244.33M
EV/Sales Ratio
1363.05x
TTM Avg
755.80x
3Y Avg
755.80x
5Y Avg
755.80x
Market Cap
$240.02M
EV/Sales Ratio
36.83x
TTM Avg
25.87x
3Y Avg
23.90x
5Y Avg
23.90x
Market Cap
$239.90M
EV/Sales Ratio
0.63x
TTM Avg
1.18x
3Y Avg
2.00x
5Y Avg
1.54x
Market Cap
$238.61M
EV/Sales Ratio
N/A
TTM Avg
1627.36x
3Y Avg
1007.98x
5Y Avg
1007.98x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Galectin Therapeutics Inc. (GALT) | $241.69M | N/A | N/A | N/A | N/A |
| Lifecore Biomedical, Inc. (LFCR)vs › | $243.62M | N/A | 2.84x | 2.61x | 2.12x |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $242.34M | N/A | N/A | N/A | N/A |
| Nautilus Biotechnolgy, Inc. (NAUT)vs › | $244.33M | 1363.05x | 755.80x | 755.80x | 755.80x |
| Q32 Bio Inc. (QTTB)vs › | $246.15M | 2.70x | 1.74x | 7.11x | 12.70x |
| Invivyd, Inc. (IVVD)vs › | $244.52M | 1.59x | 3.13x | 2.68x | 2.68x |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $240.02M | 36.83x | 25.87x | 23.90x | 23.90x |
| Akebia Therapeutics, Inc. (AKBA)vs › | $239.90M | 0.63x | 1.18x | 2.00x | 1.54x |
| InflaRx N.V. (IFRX)vs › | $238.61M | N/A | 1627.36x | 1007.98x | 1007.98x |
| SIGA Technologies, Inc. (SIGA)vs › | $238.48M | 2.26x | 1.80x | 2.97x | 3.53x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
